Targeting PARP1 for treatment of TSC and cancers
The present invention relates to methods of treating a condition associated with mTORC1 hyperactivation or TSC2-deficient cancer, the method comprising administering to a subject having the cancer a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. In some embodiments, the condition associated with mTORC1 hyperactivation is tuberous sclerosis complex (TSC). In some embodiments, the condition associated with mTORC1 hyperactivation is lymphangioleiomyomatosis (LAM). In some embodiments, the condition associated with mTORC1 hyperactivation is TSC2-deficient cancer.
1. A method of treating a condition associated with mTORC1 hyperactivation selected from tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), the method comprising administering to a subject having the condition a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor.
2. The method of claim 1 , wherein the PARP inhibitor is selected from a small molecule, a nucleic acid, a nucleic acid analog or derivative at least long enough to target a PARP1 mRNA for cleavage or binding that inhibits PARP1 protein synthesis, or combinations thereof.
3. The method of claim 1 , wherein the PARP1 inhibitor is selected from the group consisting of 8-hydroxy-2-methylquinazoline-4-one, 3,4-dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline, 3-aminobenzamide, olaparib, iniparib, rucaparib, veliparib, talazoparib, niraparib, CEP-9722, BGB-290, AG-14361, A966492 and BMN673.
4. The method of claim 2 , wherein the PARP1 inhibitor is a small interfering RNA (siRNA).
5. The method of claim 1 , wherein the subject is a mammal.
6. The method of claim 5 , wherein the subject is a human.
7. The method of claim 1 , wherein the administering is systemic.
8. The method of claim 1 , wherein the administering is local.